| Features: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Used to treat urea cycle disorders Sodium phenylbutyrate helps remove ammonia from the body. -Phenyl-butyrate (PB)4 is an aromatic fatty acid that is converted in vivo to phenylacetate (PA) by β-oxidation in liver and kidney mitochondria. -In human body, phenylbutyrate is oxidized to phenylacetate, which is in turn conjugated with glutamine and eliminated in urine as phenylacetylglutamine, thereby mediating elimination of waste nitrogen -Phenylbutyrate is one of the first drugs encountered in cancer therapy as a histone deacetylase inhibitor (HDACI) (relatively weak compared to vorinostat (SAHA), romidepsin, etc.). -Butyric acid is one of the short-chain fatty acids produced by the gut microbiota through the fermentation of dietary fiber. Butyrate is primarily recognized for its beneficial effects in the colon and is tightly linked to gut health. -Phenylbutyrate is a derivative of butyrate that has been chemically modified by the addition of a phenyl group. This structural change increases its lipophilicity (fat solubility) and alters its metabolic fate and biological activity. This allows it to be used as a systemic drug, in contrast to the locally produced butyrate in the gut, which is rapidly metabolized by colonocytes Pathways: -Histone deacetylase (HDAC) inhibitor -ER stress inhibitor (at least in normal cell) -Can act as a chemical chaperone, helping to reduce ER stress by facilitating proper protein folding. -Modulation of NF-κB Signaling -Changes in pathways such as PI3K/Akt/mTOR and MAPK. -Some preclinical investigations have reported that treatment with phenylbutyrate leads to mitochondrial dysfunction and endoplasmic reticulum (ER) stress, both of which can result in an increase of ROS within cancer cells. Note: Sodium butyrate (NaBu) vs Sodium phenylbutyrate -Sodium butyrate is primarily a research tool with limited clinical application, whereas phenylbutyrate is used clinically -Phenylbutyrate typically exhibits improved pharmacokinetics and is more amenable to systemic use compared to sodium butyrate. -Both compounds act as HDAC inhibitors, phenylbutyrate additionally modulates ER stress and mitochondrial function, leading to potentially greater ROS production in certain cancer cells. https://www.purepba.com/shop/
|
| Source: |
| Type: biomarker |
| RBM3 (RNA-binding motif protein 3) is a cold-shock protein that has garnered interest due to its involvement in RNA metabolism, stress response, and potentially tumor biology. Overall, elevated RBM3 expression tends to correlate with improved prognosis in several cancers, including breast, colorectal, ovarian, and prostate cancers, among others. Its consistent association with better outcomes has highlighted RBM3 as a promising prognostic biomarker. 3. Direction of Regulation in Cancer -Often upregulated in tumor cells relative to adjacent normal tissue. -Upregulation reflects selection for stress tolerance, not mutational activation. Important nuance: high RBM3 expression does not uniformly predict aggressiveness. 4. Dual Clinical Associations (Key Concept) A. Favorable Prognostic Association (Common in Several Solid Tumors) In breast, ovarian, colorectal, prostate, and some lung cancers: High RBM3 expression correlates with: -Better differentiation -Improved response to therapy -Longer overall survival RBM3 is best understood as a “quality-control” factor: -Tumors with controlled proliferation and intact stress responses → high RBM3, better prognosis -Tumors driven by extreme oncogenic stress (e.g., high MYC/FOXM1, chromosomal instability) → RBM3 becomes insufficient or uncoupled from control, and prognosis worsens Thus, RBM3 is not a driver, but a state marker. Therapeutic and Biomarker Implications -Biomarker: RBM3 is useful for prognostic stratification in several epithelial cancers. -Therapy response: High RBM3 often predicts better chemotherapy sensitivity, likely due to preserved apoptotic competence after damage. -Targeting: RBM3 itself is not a practical drug target; its value lies in phenotyping tumor state, not inhibition. |
| 2054- | PB, | Sodium butyrate induces ferroptosis in endometrial cancer cells via the RBM3/SLC7A11 axis |
| - | in-vitro, | EC, | ISH | - | in-vitro, | EC, | HEC1B |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:15 Target#:1242 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid